Renal cell carcinoma: Survival benefit with pembrolizumab extends to four years

A linked editorial said doctors had been waiting for more mature data.

Patients given pembrolizumab for renal cell carcinoma continue to reap the benefits at four years’ follow-up, with researchers reporting a 38% lower risk of death versus placebo.

The interim analysis of the KEYNOTE-564 trial, which included nearly 1000 adults, also points to a 28% higher likelihood of disease-free survival with adjuvant pembrolizumab (Keytruda) therapy.